Rockwell medical provides corporate and clinical update

- closes $7.5 million second tranche investment from davita -  $30 million in total capital raised this quarter - receives additional feedback from fda on its ind application wixom, mich. , june 22, 2022 /prnewswire/ -- rockwell medical, inc. (nasdaq: rmti), a biopharmaceutical company dedicated to transforming the treatment of iron deficiency and anemia management and improving outcomes for patients, today provided an update on its recent capital raise and a clinical update on safety enhancements to its planned phase 2 clinical trial of ferric pyrophosphate citrate (fpc) in home infusion patients.
DVA Ratings Summary
DVA Quant Ranking